CA
NZ
UK
AU
IND
US
Tiziana Life Sciences (NASDAQ: TLSA), a biopharmaceutical company developing innovative therapies, has drawn attention following a recent share purchase by its chairman and founder, Gabriele Cerrone.
Cuprina Holdings (NASDAQ: CUPR) has achieved a pivotal milestone with the U.S. Food and Drug Administration's clearance of its MEDIFLY Maggots. This decision, announced on June 15, 2026, opens avenues for the application of live maggots in the treatment of chronic wounds, tapping into …
SANUWAVE Health, Inc. (OTC: SNWV) has filed an 8-K report with the U.S. Securities and Exchange Commission detailing a submission for security holder votes. This step may indicate expected changes in corporate direction or governance, attracting scrutiny from investors and analysts alike.
The company secured shareholder backing for a series of corporate measures at its 2026 annual general meeting, including a reverse stock split.
A developer of Nasarix, a nasal drug delivery technology, has initiated a human study designed to evaluate the platform’s residence time in the nasal cavity. The trial marks a pivotal step in the company’s efforts to strengthen its regulatory strategy ahead of potential FDA …
On June 15, 2026, NewcelX (NASDAQ: NCEL) announced the publication of a peer-reviewed study examining its stem cell research. The company, incorporated under Swiss law, has been advancing its work in this area, and the study provides new insights into its ongoing efforts.
A diagnostics company supported by OrbiMed has announced plans to raise $250 million through a private placement of convertible senior notes. The notes, set to mature in 2031, will be offered to qualified institutional buyers under Rule 144A of the Securities Act of 1933. …
A medical device manufacturer recently disclosed the results of a shareholder vote through a regulatory filing with the U.S. Securities and Exchange Commission. The company, which operates in the orthopedic and surgical supplies industry, submitted Form 8-K under accession number **0001437749-26-020665**. Such filings are …
A regulatory compliance consultancy operating in Puerto Rico released its second-quarter financial performance, revealing gradual growth in key metrics. The firm, which provides regulatory support for pharmaceutical, biotech, and medical device clients, reported revenue for the three months ended April 30.
A Nasdaq-listed biotech firm reported a first-quarter profit for 2026, driven by financial gains tied to its Recipharm Israel operations. The company submitted a Form 6-K to the U.S. Securities and Exchange Commission on June 15, detailing the results and corporate developments.
Please wait processing your request...